Showing results (91-100 of 99) with videos related to
Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
British Journal of Cancer|December 23, 1998
Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cellsC De Giovanni, P Nanni, A Sacchi, et al.The Journal of Experimental Medicine|November 7, 2001
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic miceP Nanni, G Nicoletti, C De Giovanni, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 25, 2000
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c miceS Rovero, A Amici, E Di Carlo, et al.Oncogene|September 20, 2016
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancerL Castagnoli, G C Ghedini, A Koschorke, et al.International Journal of Cancer|June 22, 2000
p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinomaP Nanni, S M Pupa, G Nicoletti, et al.British Journal of Cancer|August 30, 2012
Human responses against HER-2-positive cancer cells in human immune system-engrafted miceC De Giovanni, G Nicoletti, L Landuzzi, et al.The Journal of Experimental Medicine|August 4, 1998
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic miceK Boggio, G Nicoletti, E Di Carlo, et al.Human Gene Therapy|February 14, 2009
A multi-DNA preventive vaccine for p53/Neu-driven cancer syndromeC De Giovanni, G Nicoletti, A Palladini, et al.Leukemia|April 26, 2016
CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemiaM Dal Bo, P Bulian, R Bomben, et al.Pageof 10